Aethlon Medical (NASDAQ:AEMD) Earns Sell Rating from Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD – Get Rating) in a report issued on Wednesday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

Separately, Maxim Group downgraded shares of Aethlon Medical from a “buy” rating to a “hold” rating in a research report on Tuesday, November 15th.

Aethlon Medical Stock Down 2.7 %

Shares of Aethlon Medical stock opened at $0.49 on Wednesday. Aethlon Medical has a twelve month low of $0.23 and a twelve month high of $2.46. The stock has a market capitalization of $11.18 million, a price-to-earnings ratio of -0.66 and a beta of 1.21. The company has a 50-day simple moving average of $0.46 and a two-hundred day simple moving average of $0.59.

Institutional Investors Weigh In On Aethlon Medical

Institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC increased its position in shares of Aethlon Medical by 11.6% in the first quarter. Renaissance Technologies LLC now owns 270,297 shares of the medical equipment provider’s stock worth $395,000 after purchasing an additional 28,097 shares during the last quarter. Natixis purchased a new stake in Aethlon Medical in the second quarter worth $28,000. Citadel Advisors LLC purchased a new position in Aethlon Medical during the third quarter valued at $72,000. Buckingham Strategic Partners purchased a new position in Aethlon Medical during the third quarter valued at $29,000. Finally, Vanguard Group Inc. raised its position in shares of Aethlon Medical by 112.9% in the 3rd quarter. Vanguard Group Inc. now owns 1,053,198 shares of the medical equipment provider’s stock worth $613,000 after purchasing an additional 558,596 shares during the last quarter. 11.86% of the stock is owned by hedge funds and other institutional investors.

Aethlon Medical Company Profile

(Get Rating)

Aethlon Medical, Inc is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. It develops Aethlon Hemopurifier, which is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The firm operates through the following segments: Aethlon and ESI.